Lyell 10-Q: Q3 Net Loss Widens to $45.5M; $194M Cash Plus $80M Placement
LYEL has more than doubled off its 52-week low of $7.195 on elevated volume (7.0× avg).
Summary
Lyell posted a wider Q3 loss of $45.5 million on higher R&D, held $194.0 million in cash at quarter-end, and disclosed an $80.0 million private placement at $10.77 per share that extends runway into 2028.
Key Events · Earnings and Guidance · LYEL
-
Q3 Loss Widens on R&D
GAAP net loss was $45.5 million versus $38.8 million a year earlier, driven by a $12.7 million increase in R&D to $40.9 million on higher clinical trial activity.
-
$80M Placement at $10.77
On November 3, 2026 Lyell agreed to sell 7,428,040 shares at $10.77 per share for gross proceeds of approximately $80.0 million, subject to customary closing conditions — below today's $14.74 quote.
-
Cash Falls to $194M
Cash, equivalents and marketable securities were $194.0 million at September 30, 2026, down from $247.2 million at December 31, 2025; nine-month operating cash burn was $107.0 million.
-
Runway Into 2028
Management states existing cash plus the $80.0 million placement funds operations through at least the next 12 months, with the concurrent 8-K citing runway into 2028.
Analysis · LYEL · Life Sciences
The balance sheet is the real story here. Lyell ended September 30 with $194.0 million in cash and securities, down from $247.2 million at year-end, and is topping that up with an $80.0 million private placement priced at $10.77 per share — below today's $14.74 quote, so the raise is dilutive at a discount to the current market. Management says the combined cash funds operations through at least the next 12 months, with the concurrent 8-K pointing to runway into 2028. On the income statement, the Q3 net loss widened to $45.5 million from $38.8 million a year earlier as R&D climbed $12.7 million to $40.9 million on heavier clinical trial activity for ronde-cel and LYL273. The pivotal ronde-cel data readout in mid-2027 and BLA in the second half of 2027 are the events that will decide the thesis.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LYEL was trading at $14.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $378.1M. The 52-week trading range was $7.20 to $45.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.